MCID: HPT003
MIFTS: 63

Hepatitis a

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Mental diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Hepatitis a

MalaCards integrated aliases for Hepatitis a:

Name: Hepatitis a 12 73 42 44 15 70
Viral Hepatitis, Type a 12
Viral Hepatitis a 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12549
MeSH 44 D006506
NCIt 50 C3096
SNOMED-CT 67 40468003
ICD10 32 B15.0 B15.9
UMLS 70 C0019159

Summaries for Hepatitis a

MedlinePlus : 42 What is Hepatitis? Hepatitis is inflammation of the liver. Inflammation is swelling that happens when tissues of the body are injured or infected. It can damage your liver. This swelling and damage can affect how well your liver functions. What is hepatitis A? Hepatitis A is a type of viral hepatitis. It causes an acute, or short-term, infection. This means that people usually get better without treatment after a few weeks. Thanks to a vaccine, hepatitis A is not very common in the United States. What causes hepatitis A? Hepatitis A is caused by the hepatitis A virus. The virus spreads through contact with an infected person's stool. This can happen if you Eat food made by someone who has the virus and did not properly wash their hands after using the bathroom Drink contaminated water or eat foods that were rinsed with contaminated water Have close personal contact with someone who has hepatitis A. This could be through certain types of sex (like oral-anal sex), taking care of someone who is ill, or using illegal drugs with others. Who is at risk for hepatitis A? Although anyone can get hepatitis A, you are at higher risk if you Travel to developing countries Have sex with someone who has hepatitis A Are a man who has sex with men Use illegal drugs Are experiencing homelessness Live with or care for someone who has hepatitis A Live with or care for a child recently adopted from a country where hepatitis A is common What are the symptoms of hepatitis A? Not everyone with hepatitis A has symptoms. Adults are more likely to have symptoms than children. If you do have symptoms, they usually start 2 to 7 weeks after infection. They can include Dark yellow urine Diarrhea Fatigue Fever Gray- or clay-colored stools Joint pain Loss of appetite Nausea and/or vomiting Abdominal pain Yellowish eyes and skin, called jaundice The symptoms usually last less than 2 months, although some people can be ill for as long as 6 months. You are at a higher risk of getting a more severe infection from hepatitis A if you also have HIV, hepatitis B, or hepatitis C. What other problems can hepatitis A cause? In rare cases, hepatitis A may lead to liver failure. This is more common in adults over age 50 and in people who have another liver. How is hepatitis A diagnosed? To diagnose hepatitis A, your health care provider may use many tools: A medical history, which includes asking about your symptoms A physical exam Blood tests, including tests for viral hepatitis What are the treatments for hepatitis A? There is no specific treatment for hepatitis A. The best way to recover is to rest, drink plenty of liquids, and eat healthy foods. Your provider may also suggest medicines to help relieve symptoms. In more severe cases, you may need care in a hospital. Can hepatitis A be prevented? The best way to prevent hepatitis A is to get the hepatitis A vaccine. It is also important to have good hygiene, especially washing your hands thoroughly after you go to the bathroom. National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Hepatitis a, also known as viral hepatitis, type a, is related to hepatitis e and hepatitis, and has symptoms including vomiting, fatigue and fever. An important gene associated with Hepatitis a is HAVCR1 (Hepatitis A Virus Cellular Receptor 1), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Neomycin and Sargramostim have been mentioned in the context of this disorder. Affiliated tissues include liver, bone and bone marrow, and related phenotypes are cardiovascular system and immune system

Disease Ontology : 12 A viral infectious disease that results in inflammation located in liver, has material basis in Hepatitis A virus, which is transmitted by ingestion of contaminated food or water, or transmitted by direct contact with an infected person. The infection has symptom fever, has symptom fatigue, has symptom loss of appetite, has symptom nausea, has symptom vomiting, has symptom abdominal pain, has symptom clay-colored bowel movements, has symptom joint pain, and has symptom jaundice.

Wikipedia : 73 Hepatitis A is an infectious disease of the liver caused by Hepatovirus A (HAV); it is a type of viral... more...

Related Diseases for Hepatitis a

Diseases in the Hepatitis family:

Hepatitis C Virus Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis B Hepatitis D
Autoimmune Hepatitis Hepatitis E
Autoimmune Hepatitis Type 2 Autoimmune Hepatitis Type 1

Diseases related to Hepatitis a via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1003)
# Related Disease Score Top Affiliating Genes
1 hepatitis e 31.6 TNF IFNG GPT F2 ALB
2 hepatitis 31.2 TNF TICAM1 SEPSECS MAVS IKBKG IFNG
3 acute kidney failure 31.2 HAVCR1 GPT F2 ALB
4 hepatitis d 31.2 IFNA1 GPT F2
5 cholestasis 31.0 SERPINA1 GPT F2 ALB
6 cholecystitis 31.0 GPT F2 ALB
7 hepatic encephalopathy 30.9 TNF GPT F2 ALB
8 acalculous cholecystitis 30.9 GPT F2 ALB
9 hepatorenal syndrome 30.8 GPT F2 ALB
10 acute pancreatitis 30.7 TNF IL1B IL10 GPT
11 hepatitis c virus 30.7 TICAM1 MAVS IFNG HAVCR2 GPT
12 drug-induced hepatitis 30.7 TNF GPT ALB
13 hepatic coma 30.7 GPT F3 F2 ALB AFP
14 viral hepatitis 30.6 TNF SERPINA1 SEPSECS IL1B IL10 IFNG
15 autoimmune hepatitis 30.6 TNF SEPSECS IL10 IFNA1 GPT F2
16 liver disease 30.5 TNF SERPINA1 SEPSECS IL1B IFNA1 GPT
17 encephalitis 30.5 TNF TICAM1 IL1B IL10
18 measles 30.4 TNF IL1B IFNG IFNA1
19 anemia, autoimmune hemolytic 30.4 GYPA CTLA4 CD4
20 alcoholic hepatitis 30.4 TNF IL1B IL10 IFNG GPT F2
21 typhoid fever 30.4 TNF IL1B IFNG GPT F2 ALB
22 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.4 IL10 IFNG CTLA4
23 rubella 30.4 TNF IL1B IL10 IFNG
24 hepatitis b 30.3 TNF IFNG IFNA1 GPT F2 CTLA4
25 granulomatous hepatitis 30.3 TNF GPT CTLA4 CD4 ALB
26 acute kidney tubular necrosis 30.3 TNF HAVCR1 GPT F2 CD4 ALB
27 poliomyelitis 30.3 TNF IL10 IFNG IFNA1 CD4
28 pertussis 30.3 TNF TICAM1 IL1B IL10
29 meningoencephalitis 30.3 TNF IL10 CD4 ALB
30 arachnoiditis 30.3 TNF IL1B CD4
31 purpura 30.2 TNF IL10 IFNG F3 F2
32 japanese encephalitis 30.2 TNF MAVS IFNA1
33 syphilis 30.2 TNF IFNG GPT F2 CD4 ALB
34 gastroenteritis 30.2 TNF IL1B IL10 IFNG IFNA1 ALB
35 hepatitis c 30.2 TNF MAVS IL10 IFNG IFNA1 GPT
36 tetanus 30.2 TNF IL1B IL10 IFNG ALB
37 mumps 30.2 TNF IL1B IL10 IFNG IFNA1
38 newcastle disease 30.2 TNF MAVS IFNA1
39 factor viii deficiency 30.1 F3 F2 ALB
40 eclampsia 30.1 TNF F2 ALB
41 dengue disease 30.1 TNF IL10 IFNG IFNA1
42 biliary atresia 30.1 IFNG GPT F2 ALB
43 sclerosing cholangitis 30.1 TNF IL10 GPT F2 CTLA4 ALB
44 acute myocarditis 30.1 TNF IL10 CD4
45 primary biliary cholangitis 30.1 SEPSECS GPT F2 CTLA4 CD4 ALB
46 non-alcoholic fatty liver disease 30.1 TNF SERPINA1 IL1B IL10 GPT ALB
47 optic neuritis 30.1 TNF IL1B IL10
48 optic nerve disease 30.0 TNF IL1B CD4 ALB
49 deficiency anemia 30.0 TNF IKBKG IFNA1 GPT F2 CD4
50 facial paralysis 30.0 TNF CD4 ALB

Graphical network of the top 20 diseases related to Hepatitis a:



Diseases related to Hepatitis a

Symptoms & Phenotypes for Hepatitis a

Symptoms:

12
  • vomiting
  • fatigue
  • fever
  • jaundice
  • abdominal pain
  • nausea
  • loss of appetite
  • joint pain
  • clay-colored bowel movements

UMLS symptoms related to Hepatitis a:


nausea and vomiting; constipation; fever; abdominal pain; pruritus; diarrhea; dyspepsia; icterus; heartburn; gastrointestinal gas

MGI Mouse Phenotypes related to Hepatitis a:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.23 ALB CTLA4 F2 F3 HAVCR2 IFNG
2 immune system MP:0005387 10.22 ALB CD4 CTLA4 F2 F3 HAVCR2
3 mortality/aging MP:0010768 10.16 AFP ALB CD4 CTLA4 F2 F3
4 digestive/alimentary MP:0005381 10.13 ALB CD4 CTLA4 F2 IFNG IKBKG
5 integument MP:0010771 10.07 CD4 CTLA4 F2 F3 IFNG IKBKG
6 liver/biliary system MP:0005370 9.92 AFP ALB CTLA4 IFNG IKBKG IL10
7 neoplasm MP:0002006 9.81 AFP ALB F3 IFNG IKBKG IL10
8 normal MP:0002873 9.61 ALB CD4 CTLA4 F2 F3 IFNG
9 respiratory system MP:0005388 9.23 CTLA4 F2 F3 IFNG IL10 MAVS

Drugs & Therapeutics for Hepatitis a

Drugs for Hepatitis a (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 944)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
2
Sargramostim Approved, Investigational Phase 4 123774-72-1, 83869-56-1
3
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
4
Simvastatin Approved Phase 4 79902-63-9 54454
5
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
6
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
7
parecoxib Approved Phase 4 198470-84-7
8
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
9
Fosamprenavir Approved Phase 4 226700-79-4 131536
10
Metformin Approved Phase 4 657-24-9 4091 14219
11
Aluminum sulfate Approved Phase 4 10043-01-3
12
Desflurane Approved Phase 4 57041-67-5 42113
13
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
14
Racepinephrine Approved Phase 4 329-65-7 838
15
Zidovudine Approved Phase 4 30516-87-1 35370
16
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
17
Atorvastatin Approved Phase 4 134523-00-5 60823
18
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
19
Didanosine Approved Phase 4 69655-05-6 50599
20
Simethicone Approved Phase 4 8050-81-5
21
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
22
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
23
Citalopram Approved Phase 4 59729-33-8 2771
24
Promethazine Approved, Investigational Phase 4 60-87-7 4927
25
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
26
Losartan Approved Phase 4 114798-26-4 3961
27
Nelfinavir Approved Phase 4 159989-64-7 64143
28
Azathioprine Approved Phase 4 446-86-6 2265
29
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8 7045767
30
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
31
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
32
Pancrelipase Approved, Investigational Phase 4 53608-75-6
33
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
34
Pentetic acid Approved Phase 4 67-43-6
35
Edetic Acid Approved, Vet_approved Phase 4 62-33-9, 60-00-4 6049
36
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
37
Ziprasidone Approved Phase 4 146939-27-7 60854
38
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
39
Tigecycline Approved Phase 4 220620-09-7 5282044
40
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
41
Polyestradiol phosphate Approved Phase 4 28014-46-2
42
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
43
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
44
Meperidine Approved Phase 4 57-42-1 4058
45
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
46
Insulin aspart Approved Phase 4 116094-23-6 16132418
47
Deferiprone Approved Phase 4 30652-11-0 2972
48
Baclofen Approved Phase 4 1134-47-0 2284
49
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
50
Remifentanil Approved Phase 4 132875-61-7 60815

Interventional clinical trials:

(show top 50) (show all 5548)
# Name Status NCT ID Phase Drugs
1 Phase IV Study of Effectiveness of Interferon and Ribavirin Treatment in Thalassemia Major Patients With Chronic Viral Hepatitis C Unknown status NCT00887081 Phase 4 PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
2 Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders Unknown status NCT01451801 Phase 4
3 Comparative Immunogenicity Study of Two Live Attenuated Hepatitis A Vaccines Unknown status NCT03231605 Phase 4
4 Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy Unknown status NCT01768195 Phase 4 Entecavir prophylaxis
5 A Randomized Controlled Trial of TACE Hepatic Artery Infusion of Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases Unknown status NCT02557490 Phase 4 oxaliplatin and raltitrexed
6 Propylactic Use of Entecavir for Biological Agents Associated Hepatitis B Virus Reactivation in Inflammatory Arthritis Patients: a Randomized Controlled Trial Unknown status NCT01907230 Phase 4 Entecavir
7 A 3-year, Open-lable, Multi-center Extension Trial of Entecavir Therapy for Patients Previously Treated in Dragon Study Unknown status NCT01829685 Phase 4 Entecavir, Adefovir
8 Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study Unknown status NCT01804387 Phase 4 telbivudine plus adefovir;lamivudine plus adefovir
9 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients-A Randomized, Double-Blinded, Controlled Trial Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
10 Open Label Study of Nucleus(t)Ide Treated Patients Randomised to Tenofovir, or Tenofovir + Telbivudine Unknown status NCT02774837 Phase 4 Tenofovir disoproxil;Telbivudine
11 Analysis of Proximal Renal Tubular Function of "Real World" Chronic Hepatitis B (CHB) Patients Who Are Suppressed on TDF and Switched to TAF Unknown status NCT02957994 Phase 4 Tenofovir alafenamide fumarate
12 Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B Unknown status NCT01925820 Phase 4 Pegasys&Entecavir
13 A Prospective Randomized, Open Labeled, Phase IV, Multicenter Study for Peginterferon Alfa-2a and Weight-based Ribavirin for 16 or 24 Weeks in genotype2 Chronic Hepatitis C Patients Who Achieved Rapid Virologic Response Unknown status NCT01056172 Phase 4 Peginterferon alfa-2a and Ribavirin;Peginterferon alfa-2a and Ribavirin
14 A Pilot Study to Evaluate the Efficacy and Safety of Pegylated Interferon Alfa-2b Plus Ribavirin in the Treatment of Patients With Dual Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4 pegylated IFN alfa-2b plus ribavirin
15 A Randomized, Multi-center, Phase IV Open-label Study Evaluating the Antiviral Efficacy of Addition of Vitamin D in Patients With Treatment Naïve Chronic Hepatitis C Receiving Peginterferon Alfa-2a Plus Ribavirin Unknown status NCT01439776 Phase 4
16 A Multi-center, Open Label, Randomized Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Capsule Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Unknown status NCT01436539 Phase 4 Adefovir Dipivoxil and polyene phosphatidylcholine;Adefovir Dipivoxil
17 Efficacy and Safety of Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With Chronic Hepatitis B Who Have Resistant Mutants to Lamivudine and Show Suboptimal Response to Combination of Lamivudine Plus Adefovir or Adefovir Monotherapy Unknown status NCT02482272 Phase 4 Lamivudine;Adefovir;Entecavir
18 A Multi Center, Phase IIIb Study to Evaluate the Efficacy of Response Guided Therapy Using Quantitative HBsAg Measurement in Patient With HBeAg Positive Chronic Hepatitis B: Unknown status NCT01456312 Phase 4 Peginterferon alfa-2a;Entecavir
19 A Single Center, Prospective Phase IV, Open-Label, Randomized Trial Comparing the Efficacy , Tolerability, and Safety of Quadritherapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide + Alfacalcidol ( Bon-One ®) ) Versus Triple Therapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide) Versus the Standard of Care Regimen(Reiferon Retard® + Ribavirin) in the Treatment of Naïve Chronic Hepatitis- C Among the Egyptian Population. Effectiveness Will be Evaluated Based on Sustained Viral Response (SVR) Unknown status NCT01896609 Phase 4 Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1
20 Phase IV Study of the Efficacy of Entecavir in Patients With Chronic Hepatitis B Virus Infection and Persistently Normal Alanine Aminotransferase Unknown status NCT01833611 Phase 4 Entecavir;placebo
21 Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma Unknown status NCT01765231 Phase 4 Entecavir prophylaxis;Observation arm
22 Efficacies of Entecavir Add on HBeAg Negative Chronic Hepatitis B Patients With HBV DNA Load ≥1000 Copies/ml After 3 Months of Peginterferon Alpha 2a Treatment Unknown status NCT02365402 Phase 4 Entecavir
23 Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients Unknown status NCT02327702 Phase 4 Emtricitabine
24 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4 Emtricitabine
25 Emtricitabine for Naive Chinese Chronic Hepatitis B Patients Unknown status NCT02327663 Phase 4 Emtricitabine
26 A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Assess the Efficacy and Safety of Fuzheng Huayu Combined With Entecavir in Liver Cirrhosis Patients Due to Hepatitis B Virus Unknown status NCT02241590 Phase 4 Entecavir + Placebo;Entecavir + Fuzheng Huayu Tablet
27 Randomized Trial of Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients Who Have Undergone Lamivudine/Adefovir Add-on Treatment Unknown status NCT01491295 Phase 4 Tenofovir disoproxil fumarate;Lamivudine plus adefovir
28 Study to Identify Eligible Subjects Using Response Guided Therapy-Stopping Rule for Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults. Unknown status NCT02822547 Phase 4 Peginterferon alfa-2a
29 The Safety and Immunogenicity of 10μg/0.5ml Recombinant Hepatitis B Vaccines(Saccharomyces Cerevisiae) in the Healthy Neonates Unknown status NCT02764671 Phase 4
30 Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C Unknown status NCT03022006 Phase 4 elbasvir, grazoprevir
31 Randomized, Multicenter, Open -Label Clinical Trial to Study the Effect of Adding on Pegylated Interferon Therapy for Patients Diagnosed With Chronic Hepatitis B Showing Maintained Response While Receiving Ongoing Nucleotide Analogues Unknown status NCT02982837 Phase 4 PEG-IFN & Nucleos(t)tide analogues;Nucleos(t)tide analogues
32 Immunogenicity and Persistence of Intramuscular High Dose Recombinant Hepatitis B Vaccine in Hemodialysis Patients in China: a Multicenter Randomized Controlled Trial Unknown status NCT02963714 Phase 4
33 An Open-label, Randomised Pilot Study Comparing the Efficacy, Safety and Tolerability of Raltegravir With Protease Inhibitor-based Therapy in Treatment-naïve, HIV/Hepatitis C Co-infected Injecting Drug Users Receiving Methadone Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
34 Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study Combining HCV and Addiction Treatment of Young Suburban Heroin Users (SHU) That Addresses Barriers to Care Unknown status NCT03364725 Phase 4 Glecaprevir-pibrentasvir
35 The Optimizing Treatment of Peginterferon Alpha in Chronic Hepatitis B Patients With Low Level HBsAg(I-Cure-3X) Unknown status NCT03801538 Phase 4 Peginterferon Alfa;Nucleoside Analog (Substance)
36 Comparison of Antiviral Efficacy of Entecavir Monotherapy and Combination Treatment With Poly IC for Chronic Hepatitis B Unknown status NCT02532413 Phase 4 Poly IC;Entecavir
37 PhaseIVstudy to Evaluate the Non-inferiority of Cavir®Tab. in Terms of Hepatitis B Virus(HBV)DNA Undetectability Comparing Baraclude® Tab. in Hepatitis B e Antigen(HBeAg)(+) Chronic Hepatitis B Patients Treated With Long-term Baraclude® Tab Unknown status NCT02523547 Phase 4 Cavir;Baraclude
38 Pilot Study to Assess the Antiviral Activity and Safety of Besifovir Dipivoxil 150mg and L-carnitine 660mg Compared to Tenofovir Alafenamide 25mg in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver Unknown status NCT03604016 Phase 4 Besifovir dipivoxil;L-carnitine;Tenofovir Alafenamide
39 Investigator Initiated Study of Thymosin in HBV-related HCC Unknown status NCT02281266 Phase 4 thymalfasin;nucleoside analog (suggest to use entecavir)
40 Efficacy of Long-term Telbivudine Treatment on Histological Improvements in Patients With Chronic Hepatitis B (EFFORT Further Extension Study) Unknown status NCT02826070 Phase 4 Telbivudine;Adefovir dipivoxil
41 The Optimizing Treatment of PegIFN Alfa in HBeAg-negative Chronic Hepatitis B Patients With Low Level HBsAg Unknown status NCT02745704 Phase 4 Peginterferon alfa
42 The Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination for Treatment of Egyptian Children and Adolescents With Chronic Hepatitis C (HCV)-Genotype 4 Unknown status NCT03743727 Phase 4 Combined therapy LDV and SOF
43 A Study Comparing the Effectiveness of Two Different Vaccination Schedules of the Combined Hepatitis A and B Vaccine(Twinrix Adult1440/20) Unknown status NCT00216229 Phase 4
44 Randomized, Multi-Center, Partially Placebo-Controlled Phase IV-Study to Compare Efficacy and Tolerability of 48-Week Combined Therapy With Peginterferon Alfa-2a, Ribavirin and Amantadine Sulphate Versus Placebo in Untreated Patients With Chronic Hepatitis C Virus-Genotype-1-Infection Unknown status NCT00127777 Phase 4 Amantadine sulphate (in addition to standard treatment)
45 Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Hepatitis B e Antigen-positive Patients With Chronic Hepatitis B Unknown status NCT01906580 Phase 4 Peg-IFNα-2a;Entecavir
46 HBsAg Clearance of Peginterferon Treatment in Patients Who Had Chronic Hepatitis B and Were on the Treatment of Nucleoside(Acid) Analogues Unknown status NCT02362490 Phase 4 peginterferon alpha 2a
47 A Prospective, Open-label, Multicenter Study of Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents Unknown status NCT02337127 Phase 4 Lamivudine
48 The Optimizing Treatment of PegIFN Alfa in HBeAg-negative Chronic Hepatitis B Patients With Low Level HBsAg Unknown status NCT02838810 Phase 4 peginterferon alfa;Nucleoside analogues
49 Pilot Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2) Unknown status NCT02768545 Phase 4 Ezetimibe
50 Personalized Medicine in HCV Infection: Cognitive Impairments and Brain Anomalies in Chronic Hepatitis C Infected Individuals. Characterization and Potential Reversibility With Direct Antiviral Agents. Unknown status NCT02745132 Phase 4

Search NIH Clinical Center for Hepatitis a

Cochrane evidence based reviews: hepatitis a

Genetic Tests for Hepatitis a

Anatomical Context for Hepatitis a

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatitis a:

19
Liver

MalaCards organs/tissues related to Hepatitis a:

40
Liver, Bone, Bone Marrow, T Cells, Kidney, Colon, Endothelial

Publications for Hepatitis a

Articles related to Hepatitis a:

(show top 50) (show all 12508)
# Title Authors PMID Year
1
Estimated Medicaid Costs Associated with Hepatitis A During an Outbreak - West Virginia, 2018-2019. 61 42
33630818 2021
2
Male-Dominant Hepatitis A Outbreak Observed among Non-HIV-Infected Persons in the Northern Part of Tokyo, Japan. 42 61
33573054 2021
3
Virus-specific memory T cell responses unmasked by immune checkpoint blockade cause hepatitis. 42
33664251 2021
4
Antiviral activity of castor oil plant (Ricinus communis) leaf extracts. 61
33515683 2021
5
Immunization status and re-immunization of childhood acute lymphoblastic leukemia survivors. 61
32882157 2021
6
Hepatitis A virus strains identified in jogaejeot associated with outbreaks in Seoul, South Korea. 61
33797771 2021
7
New Approaches to the Prevention and Treatment of Viral Diseases. 61
33811524 2021
8
Quantitative levels of norovirus and hepatitis A virus in bivalve molluscs collected along the food chain in the Netherlands, 2013-2017. 61
33662900 2021
9
Enterically transmitted hepatitis in the third millennium in northeastern Romania. 61
33603881 2021
10
Post-COVID-19 Kawasaki-Like Syndrome. 61
33765855 2021
11
Impact of social distancing on incidence of vaccine-preventable diseases, South Korea. 61
33079384 2021
12
[2nd Seroprevalence Study in Spain, 2017-2018.] 61
33734212 2021
13
Seroepidemiology of hepatitis A and B in the general population in Hong Kong: protocol of a cross-sectional survey using spatial sampling in a highly urbanised city. 61
33753433 2021
14
A genome-wide CRISPR screen identifies UFMylation and TRAMP-like complexes as host factors required for hepatitis A virus infection. 61
33730579 2021
15
Amitriptyline-Induced Acute Kidney Injury and Acute Hepatitis: A Case Report. 61
31567200 2021
16
Hepatitis A. 61
33554785 2021
17
Efficacy of Chlorine Dioxide Gas Against Hepatitis A Virus on Blueberries, Blackberries, Raspberries, and Strawberries. 61
33689143 2021
18
Differentiating Biliary Atresia From Idiopathic Neonatal Hepatitis: A Novel Keratin 7 Based Mathematical Approach on Liver Biopsies. 61
33439108 2021
19
Emphysematous hepatitis: a very rare entity with a poor prognosis. 61
33733799 2021
20
Hennepin County Adult Detention Center's Response to a 2019 Hepatitis A Outbreak in Minnesota. 61
33734843 2021
21
Hepatitis A virus-induced hsa-miR-146a-5p attenuates IFN-β signaling by targeting adaptor protein TRAF6. 61
33459883 2021
22
Hepatitis A susceptibility in newly attending men who have sex with men to an urban sexual health centre. 61
33334270 2021
23
Insight Into The Acute hepatitis A Outbreak In Indiana. 61
33763937 2021
24
Genetic aspects of adult and pediatric autoimmune hepatitis: a concise review. 61
33812046 2021
25
The major diagnostic role of autoantibodies in the diagnosis of autoimmune hepatitis, a disease of all ages. 61
33751876 2021
26
Adverse Events Following Immunization With Combined vs Concurrent Monovalent Hepatitis A and Typhoid Vaccines in Children. 61
32333678 2021
27
Effect of Plant-Derived Proteases on Infectivity of Tulane Virus, Murine Norovirus, and Hepatitis A Virus. 61
33125048 2021
28
High impact of molecular surveillance on hepatitis A outbreak case detection in Sweden: a retrospective study, 2009 to 2018. 61
33663645 2021
29
A comparative volatilomic characterization of Florence fennel from different locations: antiviral prospects. 61
33481979 2021
30
Acute liver injury following turmeric use in Tuscany: An analysis of the Italian Phytovigilance database and systematic review of case reports. 61
32656820 2021
31
Quantitative Real-Time PCR and Digital PCR to Evaluate Residual Quantity of HAV in Experimentally Depurated Mussels. 61
33730340 2021
32
Spatial and seasonal variability of human and fish viruses in mussels inside and offshore of Ravenna's harbour (Adriatic Sea, Italy). 61
32743895 2021
33
Survival and Inactivation by Advanced Oxidative Process of Foodborne Viruses in Model Low-Moisture Foods. 61
33501613 2021
34
Iminosugar glucosidase inhibitors reduce hepatic inflammation in HAV-infected Ifnar1-/- mice. 61
33692213 2021
35
Comorbidities in patients with chronic hepatitis C and hepatitis B on hemodialysis. 61
33651428 2021
36
Low Prevalence of Vaccination or Documented Immunity to Hepatitis A and Hepatitis B Viruses Among Individuals with Chronic Liver Disease. 61
33775642 2021
37
Acute Ataxia in Childhood: Clinical Presentation, Etiology, and Prognosis of Single-Center Experience. 61
32433457 2021
38
Seroprevalence and determinants of Helicobacter pylori infection in the Hispanic Community Health Study/Study of Latinos. 61
33667677 2021
39
TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients. 61
33758676 2021
40
The 2020 Nobel Prize for Medicine or Physiology for the Discovery of Hepatitis C Virus: A Triumph of Curiosity and Persistence. 61
33784424 2021
41
Safety and immunogenicity of inactivated hepatitis-A vaccine developed by Human Biologicals Institute in two age groups of healthy subjects: A phase I open label study. 61
33741190 2021
42
Hepatitis A susceptibility parallels high COVID-19 mortality. 61
32718125 2021
43
Exploratory analysis of immunization records highlights decreased SARS-CoV-2 rates in individuals with recent non-COVID-19 vaccinations. 61
33637783 2021
44
[Expert consensus on informed consent for vaccination(Part One)]. 61
33548951 2021
45
[Expert consensus on informed consent for vaccination (part one)]. 61
33548950 2021
46
Occurrence of various viruses and recent evidence of SARS-CoV-2 in wastewater systems. 61
33684818 2021
47
Maternal vaccines-safety in pregnancy. 61
33773923 2021
48
Suboptimal Vaccination Administration in Mothers With Inflammatory Bowel Disease and Their Biologic-Exposed Infants. 61
33609034 2021
49
Acquired ichthyosis and false-positive hepatitis A serology as paraneoplastic phenomena in anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma. 61
33597164 2021
50
Lessons from intensified surveillance of viral hepatitis A, Israel, 2017 and 2018. 61
33573709 2021

Variations for Hepatitis a

Expression for Hepatitis a

Search GEO for disease gene expression data for Hepatitis a.

Pathways for Hepatitis a

Pathways related to Hepatitis a according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 TNF TICAM1 SERPINA1 MAVS IL1B IL10
2
Show member pathways
13.56 TNF IL1B IL10 IKBKG IFNG IFNA1
3
Show member pathways
13.37 TNF IL1B IL10 IKBKG IFNG IFNA1
4
Show member pathways
13.19 TNF TICAM1 MAVS IL1B IL10 IKBKG
5
Show member pathways
12.96 TNF TICAM1 IL1B IKBKG IFNA1 CD4
6
Show member pathways
12.82 TNF IL1B IL10 IFNG IFNA1 CTLA4
7
Show member pathways
12.8 TNF TICAM1 MAVS IL1B IKBKG IFNG
8 12.77 TNF TICAM1 MAVS IL1B IKBKG IFNG
9
Show member pathways
12.72 TNF TICAM1 IL1B IKBKG IFNA1 F3
10
Show member pathways
12.69 TNF IL1B IKBKG IFNG CD4
11
Show member pathways
12.67 TNF IL10 IKBKG IFNG CD4
12
Show member pathways
12.58 TICAM1 MAVS IL1B IKBKG IFNA1
13
Show member pathways
12.58 TNF IL1B IL10 IKBKG IFNG CD4
14
Show member pathways
12.57 TNF MAVS IKBKG IFNG IFNA1
15
Show member pathways
12.55 TNF IL1B IL10 IKBKG IFNG F2
16
Show member pathways
12.36 TNF IL1B IKBKG IFNG
17
Show member pathways
12.34 TNF TICAM1 IL1B IKBKG IFNG
18
Show member pathways
12.34 TNF IL1B IFNG F2 ALB
19
Show member pathways
12.3 TNF TICAM1 IL1B IL10 IKBKG IFNG
20
Show member pathways
12.29 TNF IL1B IL10 IFNG IFNA1
21
Show member pathways
12.26 TNF IL1B IL10 IKBKG IFNG
22
Show member pathways
12.25 TNF IL1B IL10 IKBKG
23 12.23 TNF IL1B IL10 IFNG IFNA1
24
Show member pathways
12.22 TNF IL1B IKBKG IFNG
25
Show member pathways
12.19 TNF TICAM1 IL1B IFNG IFNA1
26 12.17 TNF TICAM1 MAVS IL1B IKBKG IFNA1
27 12.12 TNF IL1B IKBKG IFNG
28 12.07 TNF IL1B IKBKG IFNG
29 11.97 TNF IL10 IFNG GYPA CD4
30 11.96 TNF TICAM1 IL1B IKBKG
31 11.94 TNF IL1B IL10 IFNG
32 11.94 TNF TICAM1 IL1B IL10 IKBKG CD4
33 11.92 TNF IL1B GYPA CD4
34 11.89 TNF IL1B IFNG CTLA4
35 11.88 TNF TICAM1 MAVS IL1B IL10 IKBKG
36
Show member pathways
11.78 TNF IFNG CTLA4
37 11.78 TNF TICAM1 IL1B IL10
38 11.76 TNF IL1B IL10 IFNG CD4
39 11.71 TNF IL10 CTLA4
40
Show member pathways
11.69 TNF IL1B IFNG
41 11.69 TNF SERPINA1 IL1B
42
Show member pathways
11.68 TNF IL1B IL10 IFNG CD4
43 11.64 TNF IL1B IL10 IFNG CD4
44
Show member pathways
11.59 TNF IKBKG IFNG
45 11.57 TNF IL1B IL10
46 11.56 TNF IL1B IFNG
47 11.56 TNF IL1B IFNG
48 11.53 IL10 IFNG CD4
49 11.52 TNF IL1B IFNG
50 11.5 F2 ALB AFP

GO Terms for Hepatitis a

Cellular components related to Hepatitis a according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 TNF SERPINA1 IL1B IL10 IFNG IFNA1
2 extracellular space GO:0005615 9.36 TNF SERPINA1 IL1B IL10 IFNG IFNA1
3 endoplasmic reticulum lumen GO:0005788 9.35 SERPINA1 F2 CD4 ALB AFP

Biological processes related to Hepatitis a according to GeneCards Suite gene sharing:

(show all 49)
# Name GO ID Score Top Affiliating Genes
1 adaptive immune response GO:0002250 10.1 IFNG IFNA1 HAVCR2 CTLA4 CD4
2 viral process GO:0016032 10.09 TICAM1 MAVS IKBKG HAVCR1 GYPA CD4
3 inflammatory response GO:0006954 10.06 TNF TICAM1 IL1B IKBKG HAVCR2
4 cellular protein metabolic process GO:0044267 9.99 SERPINA1 F2 ALB AFP
5 defense response to virus GO:0051607 9.98 TICAM1 MAVS IFNG IFNA1
6 blood coagulation GO:0007596 9.97 SERPINA1 IFNA1 F3 F2
7 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.93 TNF TICAM1 IL1B IKBKG
8 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.91 TNF TICAM1 MAVS IKBKG CD4
9 immune response GO:0006955 9.91 TNF IL1B IL10 IKBKG IFNG CTLA4
10 positive regulation of DNA-binding transcription factor activity GO:0051091 9.88 TNF MAVS IL1B IL10
11 cellular response to lipopolysaccharide GO:0071222 9.88 TNF TICAM1 IL1B IL10 HAVCR2
12 cytokine-mediated signaling pathway GO:0019221 9.88 TNF IL1B IL10 IFNA1 F3 CD4
13 regulation of insulin secretion GO:0050796 9.87 TNF IL1B IFNG
14 negative regulation of interleukin-6 production GO:0032715 9.87 TNF IL10 HAVCR2
15 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.86 TNF IL1B HAVCR2
16 positive regulation of interferon-gamma production GO:0032729 9.85 TNF IL1B HAVCR2
17 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.85 TNF TICAM1 IKBKG
18 positive regulation of T cell proliferation GO:0042102 9.85 IL1B HAVCR2 CD4
19 positive regulation of tumor necrosis factor production GO:0032760 9.85 TICAM1 MAVS IFNG HAVCR2
20 humoral immune response GO:0006959 9.84 TNF IFNG IFNA1
21 hemostasis GO:0007599 9.82 SERPINA1 F3 F2
22 positive regulation of phagocytosis GO:0050766 9.8 TNF IL1B IFNG
23 negative regulation of T cell proliferation GO:0042130 9.8 IL10 HAVCR2 CTLA4
24 positive regulation of JAK-STAT cascade GO:0046427 9.77 TNF IL10 F2
25 lipopolysaccharide-mediated signaling pathway GO:0031663 9.77 TNF TICAM1 IL1B
26 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.76 TNF IL1B IKBKG
27 positive regulation of interleukin-8 production GO:0032757 9.76 TNF MAVS IL1B F3
28 positive regulation of cytokine production GO:0001819 9.73 TNF IL10 IFNG HAVCR2
29 negative regulation of amyloid-beta clearance GO:1900222 9.71 TNF IFNG
30 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.71 TNF IL1B IFNG
31 positive regulation of MHC class II biosynthetic process GO:0045348 9.7 IL10 IFNG
32 regulation of establishment of endothelial barrier GO:1903140 9.7 TNF IL1B
33 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.7 TNF IL1B IL10
34 endothelial cell apoptotic process GO:0072577 9.68 TNF IL10
35 vascular endothelial growth factor production GO:0010573 9.67 TNF IL1B
36 macrophage activation involved in immune response GO:0002281 9.67 TICAM1 IFNG HAVCR2